ReviewJournal of clinical medicine2021
Flecainide in Ventricular Arrhythmias: From Old Myths to New Perspectives.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The Clinical Safety and Efficacy of Sodium Channel Blocker Therapy for Rhythm Control in Atrial Fibrillation: Insights from the REGUEIFA Registry.Medical sciences (Basel, Switzerland) · 2025Observational
- Reappraising Use of Flecainide for Atrial Fibrillation and Ventricular Arrhythmias in Structural Heart Disease Patients.Medicina (Kaunas, Lithuania) · 2025Review
- Low-dose oral flecainide provocation test for Brugada syndrome: a case series.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2025Article
- Case Files from the University of California San Diego Medical Toxicology Fellowship: Neonatal Flecainide Toxicity from an Accidental Dosing Error.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2024Article
- Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator.Clinical research in cardiology : official journal of the German Cardiac Society · 2024Article
- Store-Operated CaJournal of clinical medicine · 2023Review
- Myocarditis and Myocardial Injury in Long COVID Syndrome: A Comprehensive Review of the Literature.Cureus · 2023Review
- Amitriptyline intoxication in bullfrogs causes widening of QRS complexes in electrocardiogram.The Journal of veterinary medical science · 2023Article
- Provocative testing using low dose oral flecainide for diagnosis of Brugada syndrome: a report of two cases.European heart journal. Case reports · 2022Article
- The many NOs to the use of Class IC antiarrhythmics: weren't the guidelines too strict?European heart journal supplements : journal of the European Society of Cardiology · 2022Article
- Prevalence, Management, and Outcome of Atrial Fibrillation and Other Supraventricular Arrhythmias in COVID-19 Patients.Cardiac electrophysiology clinics · 2022Review
- Prevalence and Clinical Implications of COVID-19 Myocarditis.Cardiac electrophysiology clinics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flecainide is an IC antiarrhythmic drug (AAD) that received in 1984 Food and Drug Administration approval for the treatment of sustained ventricular tachycardia (VT) and subsequently for rhythm control of atrial fibrillation (AF). Currently, flecainide is mainly employed for sinus rhythm maintenance in AF and the treatment of idiopathic ventricular arrhythmias (IVA) in absence of ischaemic and structural heart disease on the basis of CAST data. Recent studies enrolling patients with different structural heart diseases demonstrated good effectiveness and safety profile of flecainide. The purpose of this review is to assess current evidence for appropriate and safe use of flecainide, 30 years after CAST data, in the light of new diagnostic and therapeutic tools in the field of ischaemic and non-ischaemic heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.